Acute myeloid leukaemia (AML) is a heterogeneous disease in which prognosis is determined by cytogenetic and molecular aberrations as well as patient-related factors, including age, prior haematologic disorders, and comorbidities. Despite the diverse disease biology, the standard of care for remission induction therapy has changed very little since its inception in 1973. Next generation sequencing has helped to increase our knowledge of the disease pathogenesis, allowing us to develop targeted and possibly more effective treatment options. Seven new agents have been approved for the treatment of AML since 2017, all of which are directed toward a specific molecular subtype or patient population. With the advent of these therapies, a more optimal, patient-specific approach rather than the historical 'one-size fits all' model can be utilised. This review will discuss the role of these novel therapies in the remission induction setting.

中文翻译：

---

面对缓解诱导。

急性髓细胞性白血病（AML）是一种异质性疾病，其预后取决于细胞遗传学和分子畸变以及患者相关因素，包括年龄，先前的血液学疾病和合并症。尽管疾病生物学多种多样，但缓解诱导疗法的护理标准自1973年问世以来几乎没有改变。下一代测序帮助增加了我们对疾病发病机理的了解，使我们能够开发有针对性且可能更有效的治疗方案。自2017年以来，已经批准了七种新药物用于AML治疗，所有这些药物均针对特定的分子亚型或患者人群。随着这些疗法的出现，可以采用一种更优化，针对特定患者的方法，而不是采用历史悠久的“一刀切”的模式。